Literature DB >> 709559

Phase II evaluation of maytansine in patients with metastatic lung cancer.

R T Eagan, E T Creagan, J N Ingle, S Frytak, J Rubin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 709559

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  4 in total

Review 1.  Antibody-DM1 conjugates as cancer therapeutics.

Authors:  Manu Lopus
Journal:  Cancer Lett       Date:  2011-04-09       Impact factor: 8.679

2.  Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.

Authors:  Andrew C Wood; John M Maris; Richard Gorlick; E Anders Kolb; Stephen T Keir; C Patrick Reynolds; Min H Kang; Jianrong Wu; Raushan T Kurmasheva; Kathleen Whiteman; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2013-06-24       Impact factor: 3.167

Review 3.  Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; M Clerici; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models.

Authors:  Kurt Schönfeld; Peter Herbener; Chantal Zuber; Thomas Häder; Katrin Bernöster; Christoph Uherek; Jörg Schüttrumpf
Journal:  Pharm Res       Date:  2018-04-17       Impact factor: 4.200
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.